Anti-CD79a [HM57] mAb

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Name: Anti-CD79a [HM57] mAb
• Alternate name: CD79a Molecule; Membrane-Bound Immunoglobulin-Associated Protein; Surface IgM-Associated Protein; MB-1 Membrane Glycoprotein; Ig-Alpha; IGA; CD79a Antigen; MB1
• Research fields: Cancer;Cell signaling and signal transduction;Immunology;Stem cell biology
• Clone: HM57
• Tool sub type: Primary antibody
• Class: Monoclonal
• Conjugation: Unconjugated
• Reactivity: Bovine ; Chicken ; Horse ; Human ; Guinea Pig ; Mouse ; Opossum ; Pig ; Primate ; Rat ; Rabbit
• Host: Mouse
• Application: FACS ; IHC ; IP ; WB
• Description: The B-cell Antigen receptor constitutes a disulphide linked heterodimer, consisting of CD79a (mb1) and CD79b / B29 polypeptides which are non-covalently associated with membrane bound immunoglobulins on B-cells. CD79a first appears at pre B-cell stage and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in B-cell lymphomas, in B-cell lines, the majority of acute leukemias of precursor B-cell type and in some myelomas. The CD79a/b heterodimer interacts with at least one tyrosine kinase (Lyn). The induction of tyrosine kinase activity after antigen binding leads to phosphorylation of the CD79a/b dimer, and also of other molecules, thereby initiating intracellular signalling. CD79a is widely used as an adjunct to CD20 as a biomarker for normal and neoplastic B-cells in tissues sections.
• Immunogen: Synthetic peptide of 14 amino acids representing residues 202-216 of the human mb-1 cDNA sequence.
• Isotype: IgG1
• Myeloma used: P3/NS1/1-Ag4.1

Target Details

• Target: CD79a (mb1)
• Target background: The B-cell Antigen receptor constitutes a disulphide linked heterodimer, consisting of CD79a (mb1) and CD79b / B29 polypeptides which are non-covalently associated with membrane bound immunoglobulins on B-cells. CD79a first appears at pre B-cell stage and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in B-cell lymphomas, in B-cell lines, the majority of acute leukemias of precursor B-cell type and in some myelomas. The CD79a/b heterodimer interacts with at least one tyrosine kinase (Lyn). The induction of tyrosine kinase activity after antigen binding leads to phosphorylation of the CD79a/b dimer, and also of other molecules, thereby initiating intracellular signalling. CD79a is widely used as an adjunct to CD20 as a biomarker for normal and neoplastic B-cells in tissues sections.

Applications

• Application: FACS ; IHC ; IP ; WB

Handling

• Format: Liquid
• Concentration: 1 mg/ml
• Unit size: 100 ug
• Storage buffer: PBS with 0.02% azide
• Storage conditions: -15° C to -25° C
• Shipping conditions: Dry ice

References

• Mason et al. 1995. Blood. 86(4):1453-9. PMID: 7632952.
• CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples.
• Jones et al. 1993. J Immunol. 150(12):5429-35. PMID: 8515069.
• Detection of T and B cells in many animal species using cross-reactive anti-peptide antibodies.
• Mason et al. 1992. Eur J Immunol. 22(10):2753-6. PMID: 1396979.
• The B29 and mb-1 polypeptides are differentially expressed during human B cell differentiation.
• Mason et al. 1991. J Immunol. 147(11):2474-82. PMID: 1747162.
• The IgM-associated protein mb-1 as a marker of normal and neoplastic B cells.
• van Noesel et al. 1991. J Immunol. 146(11):3881-8. PMID: 2033258.
• The membrane IgM-associated heterodimer on human B cells is a newly defined B cell antigen that contains the protein product of the mb-1 gene.